Achirus japonicus extract capable of preventing and treating breast cancer and application thereof

By preparing water chestnut extract and using it in combination with capecitabine, the problem of severe toxic side effects of chemotherapy drugs in the treatment of breast cancer was solved, achieving a highly effective prevention and treatment of breast cancer, and expanding the application of water chestnut in the field of anti-tumor therapy.

CN122251507APending Publication Date: 2026-06-23AFFILIATED HOSPITAL OF NANTONG UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202610552851.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-04-24
Publication Date
2026-06-23

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_3
    Figure SMS_3
Patent Text Reader

Abstract

The application provides a cattail extract capable of preventing and treating breast cancer and an application thereof, and belongs to the technical field of biological medicine. The cattail extract is prepared by the following steps: peeling cattails, drying and crushing cattail flesh to obtain cattail flesh powder; mixing the cattail flesh powder with water to extract, filtering to obtain filtrate and residue; concentrating the filtrate to obtain a concentrate, mixing the concentrate with an ethanol solution, standing, taking the precipitate and drying to obtain dry powder 1; mixing the residue with an ethanol solution, ultrasonic extraction, taking the extract and drying to obtain dry powder 2; and mixing the dry powder 1 and the dry powder 2 to obtain the cattail extract. The cattail extract has the advantages of sufficient extraction of active ingredients, various effective components and strong overall anti-tumor effect, and can achieve an ideal effect of preventing and treating breast cancer. The cattail extract is combined with capecitabine, which can synergistically enhance the anti-breast cancer effect, reverse drug resistance, reduce toxic side effects, and greatly improve the treatment tolerance and safety.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of biomedical technology, specifically relating to a water chestnut extract that can prevent and treat breast cancer and its applications. Background Technology

[0002] Breast cancer is a highly prevalent malignant tumor that seriously threatens women's health. Currently, clinical treatments for breast cancer mainly include surgical resection, chemotherapy, radiotherapy, endocrine therapy, and targeted therapy. Among these, chemotherapy remains an important method for advanced and metastatic breast cancer, as well as for postoperative adjuvant therapy. However, existing chemotherapy drugs generally suffer from significant toxic side effects, poor patient tolerance, easy development of multidrug resistance, and decreased efficacy with long-term use. Some drugs can also cause adverse reactions such as gastrointestinal reactions, bone marrow suppression, and liver and kidney damage, seriously affecting patients' treatment adherence and quality of life. At the same time, most synthetic anti-tumor drugs are expensive, placing a significant economic burden on patients with long-term use. Therefore, developing highly effective, low-toxicity, widely available, and inexpensive natural products for the prevention and treatment of breast cancer has become a current research hotspot in the pharmaceutical field.

[0003] Water chestnuts are a traditional plant used for both food and medicine, with abundant resources and high safety. However, current technologies primarily focus on food processing and extraction of common nutrients, with a lack of systematic research on their anti-tumor activity, particularly in the prevention and treatment of breast cancer. No water chestnut extract products with clearly defined effects in preventing or treating breast cancer have been reported in publicly available media. Summary of the Invention

[0004] In view of this, one of the objectives of the present invention is to provide a water chestnut extract that can efficiently enrich the active ingredients of water chestnut and effectively prevent and treat breast cancer, which is of great significance for meeting clinical needs and expanding the application of medicinal and edible plants in the field of anti-tumor treatment.

[0005] The second objective of this invention is to provide the application of water chestnut extract in combination with capecitabine in the preparation of products for treating breast cancer. The combined use of water chestnut extract and capecitabine can synergistically enhance the anti-tumor effect of capecitabine, reverse drug resistance, reduce its toxic side effects, and improve treatment tolerance and safety.

[0006] To achieve the above-mentioned objectives, the present invention provides the following technical solution: This invention provides a water chestnut extract that can prevent and treat breast cancer, prepared by the following method: Water chestnuts are peeled, and the flesh is dried and pulverized to obtain water chestnut flesh powder; the water chestnut flesh powder is mixed with water and extracted at 60℃~70℃ for 30min~50min, then filtered to obtain filtrate and residue; the filtrate is concentrated to obtain a concentrate, which is mixed with an 85%~95% ethanol solution and allowed to stand, the precipitate is dried to obtain dried powder 1; the residue is mixed with a 60%~75% ethanol solution and ultrasonically extracted, the extract is dried to obtain dried powder 2; dried powder 1 and dried powder 2 are mixed to obtain the water chestnut extract.

[0007] Preferably, the mass-to-volume ratio of water chestnut powder to water is 1g:8~20mL; the volume ratio of the concentrate to an 85%~95% ethanol solution is 1:3~5.

[0008] Preferably, the settling temperature is 4°C and the settling time is 10h~14h.

[0009] Preferably, the mass-to-volume ratio of the filter residue to the ethanol solution with a volume fraction of 60%~75% is 1g:10~15mL; the ultrasonic extraction temperature is 60℃~80℃, the ultrasonic extraction power is 600W~700W, and the ultrasonic extraction time is 20min~40min.

[0010] Preferably, the drying includes vacuum drying, wherein the vacuum drying conditions are 50℃~60℃ and -0.08~-0.06MPa for 4~6 hours.

[0011] The present invention also provides the use of the above-mentioned water chestnut extract in the preparation of products for the prevention and / or treatment of breast cancer.

[0012] The present invention also provides the application of the above-mentioned water chestnut extract in combination with capecitabine in the preparation of products for the treatment of breast cancer.

[0013] The present invention also provides a medicament for treating breast cancer, wherein the active ingredient of the medicament includes the above-mentioned water chestnut extract.

[0014] Preferably, the active ingredient of the drug also includes capecitabine.

[0015] Preferably, the weight ratio of water chestnut extract to capecitabine is 2 to 4:1.

[0016] The beneficial effects of this invention are: The water chestnut extract prepared by the method of this invention has advantages such as sufficient extraction of active ingredients, diverse effective components, and strong overall anti-tumor effect. It can achieve ideal prevention and treatment of breast cancer, which is of great significance for meeting clinical needs and expanding the application of medicinal and edible plants in the field of anti-tumor treatment.

[0017] This invention combines water chestnut extract with capecitabine, which can synergistically enhance the anti-breast cancer effect of capecitabine, reverse drug resistance and reduce the toxic side effects of capecitabine, and significantly improve the treatment tolerability and safety of capecitabine. Detailed Implementation

[0018] This invention provides a water chestnut extract that can prevent and treat breast cancer, prepared by the following method: Water chestnuts are peeled, and the flesh is dried and pulverized to obtain water chestnut flesh powder; the water chestnut flesh powder is mixed with water and extracted at 60℃~70℃ for 30min~50min, then filtered to obtain filtrate and residue; the filtrate is concentrated to obtain a concentrate, which is mixed with an 85%~95% ethanol solution and allowed to stand, the precipitate is dried to obtain dried powder 1; the residue is mixed with a 60%~75% ethanol solution and ultrasonically extracted, the extract is dried to obtain dried powder 2; dried powder 1 and dried powder 2 are mixed to obtain the water chestnut extract.

[0019] This invention does not specifically limit the source of water chestnuts; commercially available products commonly used in the field are acceptable. In this invention, the drying temperature of the water chestnut flesh is preferably 40℃~60℃, more preferably 45℃~55℃. This invention does not specifically limit the specific method of pulverization; preferably, the pulverized water chestnuts are passed through a 60-80 mesh sieve. When mixing the water chestnut flesh powder with water, the preferred mass-to-volume ratio of water chestnut flesh powder to water is 1g:8~20mL, more preferably 1g:12~16mL. During water extraction, the preferred extraction temperature is 62℃~68℃, more preferably 64℃~66℃, and the preferred extraction time is 35min~45min. This invention does not specifically limit the specific filtration method; any filtration method that can separate the filtrate and the residue is acceptable. After obtaining the filtrate, when concentrating the filtrate, it is preferably concentrated to 1 / 3~1 / 6 of the original volume, preferably by vacuum concentration at 50℃~60℃. After obtaining the concentrate, an alcohol precipitation process is performed. The volume fraction of the ethanol solution used during precipitation is preferably 88%~92%, and the volume ratio of the concentrate to the ethanol solution is preferably 1:3~5, more preferably 1:4. In this invention, the settling temperature is preferably 4℃, and the settling time is preferably 10h~14h, more preferably 11h~13h. After settling, the precipitate is dried. The drying method is preferably vacuum drying, and the vacuum drying conditions are preferably 50℃~60℃ and -0.08~-0.06MPa for 4~6h, more preferably 53℃~56℃ and -0.07MPa for 5h.

[0020] In this invention, when the filter residue is mixed with an ethanol solution for ultrasonic extraction, the volume fraction of the ethanol solution is preferably 65%~70%, and the mass-to-volume ratio of the filter residue to the ethanol solution is preferably 1g:10mL~15mL, more preferably 1g:12mL~13mL. In this invention, the ultrasonic extraction temperature is preferably 60℃~80℃, more preferably 65℃~75℃, the ultrasonic extraction power is preferably 600W~700W, more preferably 620W~680W, and the ultrasonic extraction time is preferably 20min~40min, more preferably 25min~35min. After ultrasonic extraction, the mixture is preferably filtered, and the extract is first concentrated under reduced pressure, then dried. The temperature for reduced pressure concentration is preferably 50℃~60℃. After concentration to a paste state, the extract is dried, preferably by vacuum drying. The vacuum drying conditions are preferably 50℃~60℃ and -0.08~-0.06MPa for 4~6 hours, more preferably 53℃~56℃ and -0.07MPa for 5 hours.

[0021] This invention also provides the use of the above-mentioned water chestnut extract in the preparation of products for the prevention and / or treatment of breast cancer. This invention further provides the use of the above-mentioned water chestnut extract in combination with capecitabine in the preparation of products for the treatment of breast cancer. In this invention, the products preferably include pharmaceuticals. This invention does not specifically limit the source of capecitabine; conventional commercially available products in the art can be used. In this invention, when water chestnut extract and capecitabine are used in combination, the weight ratio of water chestnut extract to capecitabine is preferably 2-4:1, more preferably 3:1.

[0022] This invention also provides a medicament for treating breast cancer, wherein the active ingredient of the medicament includes the aforementioned water chestnut extract. In the medicament of this invention, the active ingredient preferably also includes capecitabine. When the active ingredient of the medicament is composed of water chestnut extract and capecitabine, the weight ratio of water chestnut extract to capecitabine is preferably 2-4:1, more preferably 3:1. In this invention, the medicament preferably also includes pharmaceutical excipients, which are preferably pharmaceutical excipients that do not affect the efficacy of the active ingredient.

[0023] The technical solutions provided by the present invention will be described in detail below with reference to the embodiments, but they should not be construed as limiting the scope of protection of the present invention.

[0024] Unless otherwise specified, the following embodiments are all conventional methods.

[0025] Unless otherwise specified, all materials and reagents used in the following examples are commercially available.

[0026] Example 1 A water chestnut extract that can prevent and treat breast cancer is prepared by the following method: After peeling the water chestnuts, the water chestnut flesh was dried at 40℃, pulverized, and passed through a 60-mesh sieve to obtain water chestnut flesh powder; the water chestnut flesh powder was mixed with water at a mass-volume ratio of 1g:8mL, extracted at 60℃ for 50min, and filtered to obtain filtrate and residue. The filtrate was concentrated under reduced pressure at 50°C to 1 / 3 of the original filtrate volume to obtain a concentrate. The concentrate was mixed with an 85% ethanol solution at a volume ratio of 1:3 and allowed to stand at 4°C for 10 hours. The precipitate was then dried under vacuum at 50°C and -0.06 MPa for 6 hours to obtain dried powder 1. The filter residue was mixed with a 60% ethanol solution at a mass-volume ratio of 1g:10mL, and ultrasonically extracted at 60℃ and 600W for 40min. The extract was filtered and concentrated under reduced pressure at 50℃ to a paste. Then, it was vacuum dried at 50℃ and -0.06MPa for 6h to obtain dried powder 2. Mix dried powder 1 and dried powder 2 to obtain water chestnut extract.

[0027] Example 2 A water chestnut extract that can prevent and treat breast cancer is prepared by the following method: After peeling the water chestnuts, the water chestnut flesh was dried at 60℃ and pulverized through an 80-mesh sieve to obtain water chestnut flesh powder. The water chestnut flesh powder was mixed with water at a mass-volume ratio of 1g:20mL, extracted at 70℃ for 30min, and filtered to obtain filtrate and residue. The filtrate was concentrated under reduced pressure at 60°C to 1 / 6 of the original filtrate volume to obtain a concentrate. The concentrate was mixed with a 95% ethanol solution at a volume ratio of 1:5 and allowed to stand at 4°C for 14 hours. The precipitate was then dried under vacuum at 60°C and -0.08 MPa for 4 hours to obtain dried powder 1. The filter residue was mixed with a 75% ethanol solution at a mass-volume ratio of 1g:15mL, and ultrasonically extracted at 80℃ and 700W for 20min. The extract was filtered and concentrated under reduced pressure at 60℃ to a paste. Then, it was vacuum dried at 60℃ and -0.08MPa for 4h to obtain dried powder 2. Mix dried powder 1 and dried powder 2 to obtain water chestnut extract.

[0028] Example 3 A water chestnut extract that can prevent and treat breast cancer is prepared by the following method: (1) After peeling the water chestnuts, take the water chestnut flesh, dry it at 50°C, pulverize it and pass it through an 80-mesh sieve to obtain water chestnut flesh powder; mix the water chestnut flesh powder with water at a mass-volume ratio of 1g:15mL, extract at 65°C for 40min, and filter to obtain filtrate and residue. (2) The filtrate was concentrated under reduced pressure at 55°C to 1 / 4 of the original filtrate volume to obtain a concentrate. The concentrate was mixed with an ethanol solution with a volume fraction of 90% at a volume ratio of 1:4. The mixture was allowed to stand at 4°C for 12 hours. The precipitate was then dried under vacuum at 55°C and -0.07MPa for 5 hours to obtain dried powder 1. (3) The filter residue was mixed with 70% ethanol solution at a mass-volume ratio of 1g:12mL, and ultrasonically extracted at 70℃ and 650W for 30min. The extract was filtered and concentrated under reduced pressure at 55℃ to a paste. Then, it was vacuum dried at 55℃ and -0.07MPa for 5h to obtain dried powder 2. (4) Mix dried powder 1 and dried powder 2 to obtain water chestnut extract.

[0029] Comparative Example 1 The difference from Example 3 is that it does not contain steps (3) and (4), but the rest is the same as Example 3.

[0030] Comparative Example 2 The difference from Example 3 is that the water extraction temperature in step (1) is 80°C, the volume fraction of the ethanol solution in step (2) is 80%, and the volume fraction of the ethanol solution in step (3) is 80%. The rest are the same as in Example 3.

[0031] Example 4 A composition for treating breast cancer, comprising the water chestnut extract obtained in Example 3 and capecitabine, wherein the weight ratio of water chestnut extract to capecitabine is 2:1.

[0032] Example 5 A composition for treating breast cancer, comprising the water chestnut extract obtained in Example 3 and capecitabine, wherein the weight ratio of water chestnut extract to capecitabine is 4:1.

[0033] Example 6 A composition for treating breast cancer, comprising the water chestnut extract obtained in Example 3 and capecitabine, wherein the weight ratio of water chestnut extract to capecitabine is 3:1.

[0034] Comparative Example 3 The difference from Example 6 is that the water chestnut extract is replaced with the dried powder 1 of Comparative Example 1, and the rest are the same as in Example 6.

[0035] Comparative Example 4 The difference from Example 6 is that the water chestnut extract is replaced with the water chestnut extract of Comparative Example 2, and the rest are the same as in Example 6.

[0036] Comparative Example 5 The difference from Example 6 is that the weight ratio of water chestnut extract to capecitabine is 5:1, while the rest are the same as in Example 6.

[0037] Comparative Example 6 The difference from Example 6 is that the weight ratio of water chestnut extract to capecitabine is 3:2, while the rest are the same as in Example 6.

[0038] Experimental Example 1 Using drug-resistant breast cancer MDA-MB-468 cells as the experimental subject, a cell proliferation inhibition assay (CCK-8 assay) was performed. The specific method is as follows: The experimental groups were set as follows: Example 3, Comparative Example 1, Comparative Example 2, Example 6, Capecitabine, Comparative Example 3, Comparative Example 4, Comparative Example 5 and Comparative Example 6.

[0039] In 96-well plates, 4000 MDA-MB-468 cells were seeded in each well. After cell attachment, culture media containing different concentrations of the following: water chestnut extract obtained in Example 3, dried powder 1 obtained in Comparative Example 1, water chestnut extract obtained in Comparative Example 2, the composition obtained in Example 6, capecitabine, the composition obtained in Comparative Example 3, the composition obtained in Comparative Example 4, the composition obtained in Comparative Example 5, and the composition obtained in Comparative Example 6. A culture medium without added exogenous substances served as a control group. After 72 hours of treatment, CCK-8 was added, and the plates were incubated in a CO2 incubator for 1 hour. The absorbance at 450 nm was then read using a microplate reader. The cell proliferation inhibition rate was calculated as (A control group - A treatment group) / A control group. Each group was tested in quadruplicate, and the final result was the average.

[0040] Calculate the inhibitory IC50 of each group on breast cancer cell proliferation. 50 The results are shown in Table 1. This indicates that the water chestnut extract provided by this invention has inhibitory activity against breast cancer cell proliferation. The combined application of water chestnut extract and capecitabine significantly enhances its inhibitory activity against breast cancer cell proliferation.

[0041] Table 1. Inhibition results of different groups on breast cancer cell proliferation

[0042] Experimental Example 2 Using drug-resistant breast cancer MDA-MB-468 cells as the experimental subject, a cell migration assay was performed. The specific method is as follows: Scratch assay to determine the activity against breast cancer cell migration: 2 × 10⁶ cells / well in each 12-well plate. 5MDA-MB-468 cells in logarithmic growth phase were seeded at a certain cell mass. After 24 hours of cell adhesion, the cells were scratched with a pipette tip. Floating cells were washed away with PBS. Culture media containing the same concentrations of the following: water chestnut extract obtained in Example 3, dried powder 1 obtained in Comparative Example 1, water chestnut extract obtained in Comparative Example 2, the composition obtained in Example 6, capecitabine, the composition obtained in Comparative Example 3, the composition obtained in Comparative Example 4, the composition obtained in Comparative Example 5, and the composition obtained in Comparative Example 6 were added. After 24 hours, the cells were stained with crystal violet and photographed under a microscope. The change in scratch area before and after treatment was statistically analyzed. The group without any added exogenous substances served as the blank control group. The migration inhibition rate was calculated as [(scratch healing rate of blank control group - scratch healing rate of treated group) / scratch healing rate of blank control group] × 100%, where scratch healing rate (%) = [(0h scratch width - 24h scratch width) / 0h scratch width] × 100%. Each group was subjected to four parallel experiments, and the final result was the average value.

[0043] The results are shown in Table 2, indicating that the water chestnut extract provided by the present invention has the activity of inhibiting the migration of breast cancer cells. When the water chestnut extract is used in combination with capecitabine, its activity of inhibiting the migration of breast cancer cells is significantly enhanced.

[0044] Table 2. Inhibition rate of breast cancer cell migration in different groups

[0045] Experimental Example 3 I. Pre-experiment preparation (a) Test materials Experimental animals: female nude mice (BALB / c-nu / nu), 4-6 weeks old, weighing 18-22g, 10 groups of 7 mice each, purchased from a regular experimental animal center and housed in an SPF-grade animal room (temperature 22±2℃, humidity 55±5%, 12h light-dark cycle, free access to food and water), and modeling began after 3 days of acclimatization.

[0046] Tumor cells: MDA-MB-231 cells (triple-negative breast cancer cells, clinically refractory, moderately sensitive to capecitabine, meeting the requirements of the assay), logarithmic growth phase cells, concentration adjusted to 1×10⁻⁶. 7 Quantity / mL, for later use.

[0047] Test drugs: Water chestnut extract (WE) of Example 3, dried powder 1 of Comparative Example 1, water chestnut extract of Comparative Example 2; composition of Example 6, composition of Comparative Example 3, composition of Comparative Example 4, composition of Comparative Example 5, composition of Comparative Example 6; capecitabine (CAP) standard.

[0048] Drug preparation: All extracts, dried powders, and compositions were dissolved by sonication in physiological saline (a small amount of DMSO was added to aid dissolution in Examples 6 and Comparative Examples 3-6, with a final DMSO concentration <0.1% to avoid damaging nude mice), stirred thoroughly, filtered for sterilization, and used immediately; the dosage was based on the IC50 of the cell assay. 50 and conversion of nude mouse body surface area (nude mouse body surface area formula: body surface area (cm²)) 2 =0.0061 × body weight (g) + 0.052), ensuring that the dose is within the routine range for in vivo testing.

[0049] Reagents and instruments: Vernier calipers (accuracy 0.01mm), electronic balance (accuracy 0.001g), centrifuge, ELISA reader, formaldehyde solution, HE staining kit, liver and kidney function test kit, blood routine test kit, related antibodies (Ki67, Bax, Bcl-2), etc.

[0050] (II) Construction of a nude mouse xenograft model of breast cancer 1. Cell preparation: MDA-MB-231 cells in logarithmic growth phase were digested, centrifuged, resuspended in sterile physiological saline, and the cell concentration was adjusted to 1×10⁻⁶. 7 Inoculation rate: 1 / mL, store on ice, and complete inoculation within 30 minutes.

[0051] 2. Inoculation procedure: After anesthetizing nude mice with an intraperitoneal injection of 1% sodium pentobarbital (50 mg / kg), the skin under the right armpit was disinfected with 75% alcohol. 0.1 mL of cell suspension (containing 1 × 10⁻⁶ cells) was drawn using a 1 mL sterile syringe. 6 (1 cell) was injected subcutaneously into the right armpit of a nude mouse (avoiding blood vessels), and the injection site was gently pressed for 10 seconds to prevent extracellular leakage of cells.

[0052] 3. Model Validation: After inoculation, the nude mice were observed daily for their mental state and for any redness, swelling, or ulceration at the inoculation site. The long diameter (a) and short diameter (b) of the axillary tumor were measured weekly using calipers, and the tumor volume was calculated (V = 1 / 2 × a × b). 2 When the tumor grows to 100-200 mm... 3 Once the model was considered successfully constructed, the nude mice were randomly divided into 10 groups of 7 mice each. The average weight and average tumor volume of the nude mice in each group were kept from being significantly different (P>0.05), and then the drug administration was started.

[0053] II. Specific Animal Experiment Design (including all examples and comparative groupings) (a) Experimental grouping (10 groups, including all comparative samples as controls, 7 nude mice in each group) The specific groupings and medication details are shown in Table 3.

[0054] Table 3 Experimental Groups

[0055] Additional notes: All groups were administered the medication at 9:00 AM daily. After administration, the mice were observed for 1 hour, and any abnormal reactions such as vomiting or convulsions were recorded. Sterile gavage needles were used for gavage.

[0056] (II) Testing Indicators and Operating Procedures 1. Tumor growth markers (1) Detection time: before drug administration (when the modeling is successful, it is recorded as D0) and on the 21st day of drug administration (D21, the end of drug administration).

[0057] (2) Detection procedure: Weigh the nude mouse using an electronic balance (accurate to 0.01g), measure the major diameter (a) and minor diameter (b) of the tumor using vernier calipers (accurate to 0.01mm), and calculate the tumor volume (V=1 / 2×a×b). 2 After the administration was completed, the nude mice were euthanized by cervical dislocation, the tumor tissue under the right axilla was dissected, and the tumor weight was measured using an electronic balance (accurate to 0.001g).

[0058] (3) Calculation index: Tumor inhibition rate (%) = (average tumor weight of blank control group - average tumor weight of drug treatment group) / average tumor weight of blank control group × 100%.

[0059] 2. Toxic and side effect indicators (1) General observation: Observe the mental state (active / listless), diet and water intake, fur condition (smooth / messy), and activity level of nude mice every day, and record whether there is death or poisoning symptoms (vomiting, diarrhea, skin ulceration). Weigh the mice weekly and calculate the weight change rate (%) = (D21 weight - D0 weight) / D0 weight × 100% (weight loss > 10% is considered to be obviously toxic).

[0060] (2) Serum biochemistry and routine blood tests: After the administration of the drug, blood was collected from the orbital cavity of nude mice (0.5-1 mL per mouse), and the serum was separated by centrifugation (3000 r / min, 15 min). Liver and kidney function indicators (ALT: alanine aminotransferase, AST: aspartate aminotransferase, BUN: blood urea nitrogen, Cr: creatinine) and routine blood indicators (WBC: white blood cells) were detected by an enzyme-linked immunosorbent assay (ELISA) reader. All indicators were tested strictly in accordance with the instructions of the kit.

[0061] (III) Statistical Analysis Data were analyzed using SPSS 26.0 software. All test data are expressed as mean ± standard deviation (x ± s). One-way ANOVA was used for comparisons between groups, and LSD-t test was used for pairwise comparisons. P < 0.05 was considered statistically significant, and P < 0.01 was considered highly statistically significant. Synergistic effect determination: The tumor inhibition rate of the Example 6 group was greater than the sum of the inhibition rates of the Example 3 group and the capecitabine monotherapy group, and P < 0.01.

[0062] III. Experimental Results and Analysis (a) Results of tumor growth-related indicators The results of tumor growth-related indicators for different groups are shown in Table 4.

[0063] Table 4 Results of tumor growth-related indicators in different groups

[0064] Note: This indicates that p < 0.01 compared to the model control group.

[0065] As shown in Table 4, the tumor inhibition rate of the Example 6 group was significantly higher than that of all other drug administration groups, and significantly higher than the sum of the Example 3 group and the capecitabine group, clearly achieving a synergistic effect. The tumor inhibition rate of the Example 3 group was significantly higher than that of Comparative Example 1 and Comparative Example 2, proving that the extraction process of Example 3 can significantly enhance the anti-breast cancer activity of water chestnut extract. The tumor inhibition rate of the Example 6 group was significantly higher than that of all comparative example composition groups; Comparative Example 3 showed antagonism, Comparative Example 4 showed weak additive effect, and Comparative Examples 5-6 showed weak synergy, none of which achieved the strong synergistic effect of the Example 6 group, proving that the weight ratio (3:1) of the composition and the quality of the extract in Example 6 are the key to achieving synergistic effects.

[0066] (II) Results of indicators related to toxic side effects 1. The general condition and weight changes of nude mice are shown in Table 5. This indicates that the water chestnut extract of the present invention has no toxic side effects, and that the combined application of water chestnut extract and capecitabine can effectively reduce the toxic side effects of capecitabine.

[0067] Table 5. Results of general condition and weight changes in nude mice.

[0068] Note: This indicates that p < 0.05 compared to the model control group; This indicates that p < 0.01 compared to the model control group.

[0069] 2. The serum biochemical and blood routine test results of some groups are shown in Table 6. This indicates that the water chestnut extract of the present invention has no toxic side effects, and that the combined use of water chestnut extract and capecitabine can effectively reduce the toxic side effects of capecitabine.

[0070] Table 6. Results of serum biochemistry and routine blood tests

[0071] Note: This indicates that p < 0.01 compared to the model control group.

[0072] The above description is only a preferred embodiment of the present invention. It should be noted that for those skilled in the art, several improvements and modifications can be made without departing from the principle of the present invention, and these improvements and modifications should also be considered within the scope of protection of the present invention.

Claims

1. A chufa extract capable of preventing breast cancer, characterized in that, The following preparation method was used to obtain the water chestnut extract: After peeling the water chestnuts, the flesh was dried and pulverized to obtain water chestnut flesh powder; the water chestnut flesh powder was mixed with water and extracted at 60℃~70℃ for 30min~50min, and filtered to obtain filtrate and residue; the filtrate was concentrated to obtain concentrate, and the concentrate was mixed with an 85%~95% ethanol solution and allowed to stand, and the precipitate was dried to obtain dried powder 1; the residue was mixed with a 60%~75% ethanol solution and ultrasonically extracted, and the extract was dried to obtain dried powder 2; dried powder 1 and dried powder 2 were mixed to obtain water chestnut extract.

2. The extract of Eleocharis tuberosa according to claim 1, characterized in that, The mass-to-volume ratio of water chestnut powder to water is 1g:8~20mL; the volume ratio of the concentrate to an 85%~95% ethanol solution is 1:3~5.

3. The extract of Eleocharis tuberosa according to claim 1, characterized in that, The settling temperature is 4°C, and the settling time is 10h~14h.

4. The extract of Eleocharis tuberosa according to claim 1, characterized in that, The mass-to-volume ratio of the filter residue to the ethanol solution with a volume fraction of 60%~75% is 1g:10~15mL; the ultrasonic extraction temperature is 60℃~80℃, the ultrasonic extraction power is 600W~700W, and the ultrasonic extraction time is 20min~40min.

5. The extract of Eleocharis tuberosa according to claim 1, characterized in that, The drying process includes vacuum drying, wherein the vacuum drying conditions are 50℃~60℃ and -0.08~-0.06MPa for 4~6 hours.

6. The use of the water chestnut extract according to any one of claims 1 to 5 in the preparation of products for the prevention and / or treatment of breast cancer.

7. The use of the water chestnut extract according to any one of claims 1 to 5 in combination with capecitabine in the preparation of a product for treating breast cancer.

8. A medicament for treating breast cancer, characterized by comprising a compound of the formula (I) or a pharmaceutically acceptable salt thereof. The active ingredient of the drug includes the water chestnut extract as described in any one of claims 1 to 5.

9. The medicament according to claim 8, characterized in that, The active ingredient in the drug also includes capecitabine.

10. The medicament according to claim 9, characterized in that, The weight ratio of water chestnut extract to capecitabine is 2-4:1.